Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Eterna Therapeutics Inc (ERNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ERNA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.95% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.62M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 7.12 | 52 Weeks Range 1.75 - 39.45 | Updated Date 06/29/2025 |
52 Weeks Range 1.75 - 39.45 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -32.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2652.9% |
Management Effectiveness
Return on Assets (TTM) -32.42% | Return on Equity (TTM) -2264.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14647264 | Price to Sales(TTM) 25.45 |
Enterprise Value 14647264 | Price to Sales(TTM) 25.45 | ||
Enterprise Value to Revenue 27.38 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 7361200 | Shares Floating 1664157 |
Shares Outstanding 7361200 | Shares Floating 1664157 | ||
Percent Insiders 61.04 | Percent Institutions 1.35 |
Upturn AI SWOT
Eterna Therapeutics Inc
Company Overview
History and Background
Eterna Therapeutics Inc. (ETNB) is a biotechnology company focused on developing messenger RNA (mRNA) based therapies for various diseases. Founded in 2015, Eterna is leveraging mRNA technology to develop novel treatments, including cancer immunotherapies and vaccines.
Core Business Areas
- mRNA Therapeutics Development: Development of novel mRNA-based therapies for oncology, infectious diseases, and other therapeutic areas. Focuses on discovery, preclinical development, and clinical trials.
- mRNA Technology Platform: Optimization and expansion of its mRNA technology platform, including delivery systems and therapeutic targets.
Leadership and Structure
Dr. Robert Gagnon serves as the CEO. The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- ETX201: A cancer immunotherapy candidate in preclinical development. Targets solid tumors using mRNA delivery of immune-modulating agents. Competitors include Moderna and BioNTech, which are developing similar mRNA-based cancer therapies. Limited market share at this stage, as it is in preclinical.
- ETX301: A vaccine candidate being developed for infectious diseases. Utilizes mRNA to encode viral antigens and elicit an immune response. Competitors include Pfizer and Moderna in mRNA vaccine development. Limited market share at this stage, as it is in preclinical.
Market Dynamics
Industry Overview
The mRNA therapeutics market is experiencing significant growth, driven by the success of mRNA vaccines during the COVID-19 pandemic. This has led to increased investment and interest in mRNA-based therapies for a wide range of diseases.
Positioning
Eterna Therapeutics Inc. is a relatively small player in the mRNA therapeutics market. It is focused on developing innovative mRNA-based therapies and vaccines to address unmet medical needs. Competitive advantages include its proprietary mRNA delivery technology.
Total Addressable Market (TAM)
The global mRNA therapeutics market is projected to reach over $98.7 billion by 2030. Eterna is positioned to capture a portion of this market through its pipeline of preclinical assets and technology platform.
Upturn SWOT Analysis
Strengths
- Proprietary mRNA delivery technology
- Experienced leadership team
- Focus on innovative mRNA-based therapies
- Early-stage pipeline with potential
Weaknesses
- Limited financial resources compared to larger competitors
- Early-stage pipeline with high risk of failure
- Limited market presence
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of mRNA technology platform
- Advancement of pipeline candidates into clinical trials
- Potential for breakthrough therapies in unmet medical needs
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and approval timelines
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- LLY
Competitive Landscape
Eterna Therapeutics Inc. faces strong competition from larger pharmaceutical companies with established mRNA technology platforms. Its success depends on demonstrating the efficacy and safety of its pipeline candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily measured by progress in preclinical development and technology platform advancement.
Future Projections: Future growth is contingent on clinical trial success, partnerships, and potential FDA approvals. Analyst estimates are not readily available.
Recent Initiatives: Focusing on progressing its pipeline candidates into clinical trials and expanding its mRNA technology platform.
Summary
Eterna Therapeutics Inc. is a early-stage biotechnology company focused on mRNA therapeutics. It faces considerable competition and financial challenges but possesses promising technology and a focused pipeline. Success will depend on progressing candidates to clinical trials, securing partnerships, and demonstrating efficacy. The company needs to manage its cash flow carefully and capitalize on the growing mRNA market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eterna Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1992-10-19 | CEO, President & Director Mr. Sanjeev Luther | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.ernexatx.com |
Full time employees 6 | Website https://www.ernexatx.com | ||
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.